

LESS
doubt



MORE
confidence



MORE than a test


Xpert® Xpress CoV-2/Flu/RSV *plus*

When you need to know if it's the flu, COVID-19, or RSV, choose a test that delivers more. One that combines enhanced gene coverage and multiplex viral detection.

Coverage, plus
Accuracy, plus
Peace of mind

That's the **PCR*plus*** advantage.
From Cepheid.


Visit www.cepheid.com/coronavirus




SARS-CoV-2



Flu A



Flu B



RSV

Coverage, plus

Viruses constantly change through mutation, and these mutations can give rise to new variants with unique characteristics. Cepheid has proactively addressed this increasing diversity by **enhancing gene coverage**.

The Xpert® **Xpress** CoV-2/Flu/RSV **plus** test provides a third gene target for SARS-CoV-2 as well as an optimization of nucleocapsid gene probes to enable more reliable virus detection.

Gene Targets

SARS-CoV-2	Flu A	Flu B	RSV
RdRP RNA-dependent RNA polymerase gene	M Matrix gene	M Matrix gene	RSV A Nucleocapsid gene
E Envelope protein gene	PB2 polymerase basic protein 2 gene	NS non-structural protein gene	RSV B Nucleocapsid gene
N2 Nucleocapsid gene	PA polymerase acidic protein gene		

Accuracy, plus

In the Xpert **Xpress** CoV-2/Flu/RSV **plus** test, the addition of primer/probe sets for the detection of a third SARS-CoV-2 target, RdRP, will add further **redundancy for greater confidence in detection**.

In addition, Flu and RSV detection is achieved through comprehensive design across seven unique and independent targets to ensure optimum coverage and to mitigate the effects of seasonal antigenic shift and drift.

Peace of mind

Molecular methods targeting **multiple gene targets** within the viral genome allow for more reliable detection of strains undergoing genetic variation.*

The Xpert **Xpress** CoV-2/Flu/RSV **plus** test has been designed to give healthcare providers **confidence in their results and decisions**.

Choose the **PCRplus** advantage.
Get **MORE** than results.

* "Tests with multiple targets are more likely to continue to perform as described in the test's labeling as new variants emerge. Multiple targets means that a molecular test is designed to detect more than one section of the SARS-CoV-2 genome." <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests>

This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens.

This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

CORPORATE HEADQUARTERS

904 Caribbean Drive
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Soleih
81470 Maurens-Scopont France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAIL cepheid@cepheideurope.fr

www.Cepheid.com

© 2022 Cepheid 0897-01